MCID: DNG001
MIFTS: 40

Dengue Shock Syndrome

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dengue Shock Syndrome

MalaCards integrated aliases for Dengue Shock Syndrome:

Name: Dengue Shock Syndrome 12 52 14 69
Dss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050125

Summaries for Dengue Shock Syndrome

Disease Ontology : 12 A dengue disease that involves the most severe form of dengue fever, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted_by Aedes mosquito bite. The infection has symptom easy bruising, has symptom blood spots, has symptom bleeding gums, and has symptom nosebleeds. It is accompanied by circulatory collapse, involves hypotension, narrow pulse pressure (less than or equal to 20mm Hg), or frank shock. The shock occurs after two to six days of symptoms, followed by collapse, weak pulse, and blueness around the mouth.

MalaCards based summary : Dengue Shock Syndrome, also known as dss, is related to malaria and dengue disease. An important gene associated with Dengue Shock Syndrome is THBD (Thrombomodulin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Toll-Like receptor Signaling Pathways. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, testes and skin.

Related Diseases for Dengue Shock Syndrome

Diseases related to Dengue Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
id Related Disease Score Top Affiliating Genes
1 malaria 26.6 CCL2 HLA-A IL1B IL1RN IL6 THBD
2 dengue disease 11.7
3 dengue fever, protection against 11.0
4 gastric cancer risk after h. pylori infection 10.7 IL1B IL1RN
5 tabatznik syndrome 10.6 IL1B TNF
6 sternal cleft 10.6 IL1B TNF
7 cutaneous solitary mastocytoma 10.6 CMA1 TPSAB1
8 pulmonary hypertension 10.6 IL1B TNF
9 milk allergy 10.6 IL1B IL1RN
10 oculomotor nerve paralysis 10.6 IL1B IL6
11 common peroneal nerve lesion 10.5 IL1B IL6
12 cataract 10.5 IL1B TNF
13 bladder calculus 10.5 IL1RN TNF
14 crystal arthropathies 10.5 IL1RN IL6
15 smarca4-deficient sarcoma of thorax 10.5 IL6 TNF
16 shoulder impingement syndrome 10.5 IL1RN IL6
17 aortic arch interruption 10.5 IL6 TNF
18 cutaneous leishmaniasis 10.4 IL6 TNF
19 x-linked dominant intellectual disability-epilepsy syndrome 10.4 IL1B IL6
20 spirillary rat-bite fever 10.4 IL6 TNF
21 infancy electroclinical syndrome 10.4 IL1B IL6
22 toxoplasmosis 10.4 IL6 TNF
23 dyslexia 5 10.4 IL6 TNF
24 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.4 IL1B TNF
25 mental retardation dysmorphism hypogonadism diabetes 10.4 IL1B IL1RN THBD
26 epstein-barr virus hepatitis 10.4 IL6 TNF
27 anencephaly and spina bifida x-linked 10.4 IL6 TNF
28 walker dyson syndrome 10.3 IL1B IL1RN TNF
29 hemorrhagic fever 10.3
30 dengue hemorrhagic fever 10.3
31 senile reticular retinal degeneration 10.3 IL1B IL1RN TNF
32 vagina leiomyosarcoma 10.3 IL1RN IL6
33 tibialis tendinitis 10.3 IL1B IL1RN TNF
34 extrahepatic bile duct papillary adenoma 10.3 IL1B IL1RN TNF
35 papilledema 10.3 IL6 TNF
36 congenital nonspherocytic hemolytic anemia 10.3 IL1B IL6
37 plantar fascial fibromatosis 10.3 IL1B IL1RN TNF
38 retinal vascular occlusion 10.3 IL1B IL1RN TNF
39 ethmoid sinus adenocarcinoma 10.3 IL6 TNF
40 hernia of ovary and fallopian tube 10.3 HLA-A IL1RN
41 moved to 244450 10.2 IL1B TNF
42 scrotal carcinoma 10.2 IL1B IL6 TNF
43 upper gum cancer 10.2 IL1B IL6 TNF
44 bipolar i disorder 10.2 IL1B IL6 TNF
45 tinea favosa 10.2 IL1B IL6 TNF
46 central nervous system leiomyosarcoma 10.2 IL1B IL6 TNF
47 early-onset zonular cataract 10.2 IL1B IL6 TNF
48 acquired thrombocytopenia 10.2 IL1B IL6 TNF
49 ampulla of vater neoplasm 10.2 IL1B IL6 TNF
50 brucella canis brucellosis 10.2 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Dengue Shock Syndrome:



Diseases related to Dengue Shock Syndrome

Symptoms & Phenotypes for Dengue Shock Syndrome

Drugs & Therapeutics for Dengue Shock Syndrome

Drugs for Dengue Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Anti-Allergic Agents Phase 4
4 Antipruritics Phase 4
5 Dermatologic Agents Phase 4
6 Histamine Antagonists Phase 4
7 Histamine H1 Antagonists Phase 4
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Neurotransmitter Agents Phase 4
10
Ivermectin Approved, Vet_approved Phase 2, Phase 3 70288-86-7 6474909 46936176
11 Pharmaceutical Solutions Phase 3,Phase 2
12 Anti-Infective Agents Phase 2, Phase 3
13 Antiparasitic Agents Phase 2, Phase 3
14 Vaccines Phase 3,Phase 2,Phase 1
15 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
16
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
17
Ribavirin Approved Phase 2 36791-04-5 37542
18
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
19 Antimetabolites Phase 2
20 Antiviral Agents Phase 2
21 Cortisol succinate Phase 2
22 Hydrocortisone 17-butyrate 21-propionate Phase 2
23 Hydrocortisone acetate Phase 2
24 Antibodies Phase 1, Phase 2
25 Immunoglobulins Phase 1, Phase 2
26
Aluminum hydroxide Approved Phase 1 21645-51-2
27
Aluminum sulfate Approved Phase 1 10043-01-3
28 Adjuvants, Immunologic Phase 1
29 Antacids Phase 1
30 Anti-Ulcer Agents Phase 1
31 Gastrointestinal Agents Phase 1
32 gamma-Globulins
33 Immunoglobulins, Intravenous
34 Rho(D) Immune Globulin

Interventional clinical trials:

(show top 50) (show all 96)

id Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Recruiting NCT02673840 Phase 4 Ketotifen;Placebo
2 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
4 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
5 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
6 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
7 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
8 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
9 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
10 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Active, not recruiting NCT01373281 Phase 3
11 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
12 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
13 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Active, not recruiting NCT01374516 Phase 3
14 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
15 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
16 Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia Completed NCT01218906 Phase 2
17 Study of Febrile Illness for Dengue-Endemic Areas in Latin America Completed NCT01293331 Phase 1, Phase 2
18 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
19 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
20 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
21 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
22 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
23 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
24 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
25 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
26 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
27 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
28 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
29 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
30 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
31 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
32 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
33 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
34 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
35 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
36 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Recruiting NCT03110770 Phase 2
37 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
38 Immunogenicity and Safety of 3-Dose and Booster Dose of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
39 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
40 Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Active, not recruiting NCT02302066 Phase 2 TDV Placebo
41 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
42 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
43 A Study of Balapiravir in Patients With Dengue Virus Infection Completed NCT01096576 Phase 1 balapiravir [RO4588161];placebo
44 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Completed NCT01224639 Phase 1
45 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Completed NCT00458120 Phase 1
46 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults Completed NCT00089908 Phase 1
47 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults Completed NCT00094705 Phase 1
48 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults Completed NCT00270699 Phase 1
49 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Completed NCT00831012 Phase 1
50 Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus Completed NCT00919178 Phase 1

Search NIH Clinical Center for Dengue Shock Syndrome

Genetic Tests for Dengue Shock Syndrome

Anatomical Context for Dengue Shock Syndrome

MalaCards organs/tissues related to Dengue Shock Syndrome:

39
Endothelial, Testes, Skin, Heart, Liver, Bone, Bone Marrow

Publications for Dengue Shock Syndrome

Articles related to Dengue Shock Syndrome:

(show top 50) (show all 135)
id Title Authors Year
1
The value of daily platelet counts for predicting dengue shock syndrome: Results from a prospective observational study of 2301 Vietnamese children with dengue. ( 28448490 )
2017
2
Vitamin D serostatus and dengue fever progression to dengue hemorrhagic fever/dengue shock syndrome. ( 28903788 )
2017
3
Dengue shock syndrome with retroperitoneal haematoma requiring repeated artery angioembolization. ( 28889142 )
2017
4
Dengue shock syndrome. ( 28031845 )
2016
5
Clinical Characteristics and Risk Factors of Dengue Shock Syndrome in Children. ( 27455442 )
2016
6
Delayed subdural hematoma after recovery from dengue shock syndrome. ( 27114678 )
2016
7
In silico transcriptional regulation and functional analysis of dengue shock syndrome associated SNPs in PLCE1 and MICB genes. ( 27038471 )
2016
8
State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. ( 27553703 )
2016
9
Fatal invasive aspergillosis: a rare co-infection with an unexpected image presentation in a patient with dengue shock syndrome. ( 26072955 )
2015
10
Alpha tryptase allele of Tryptase 1 (TPSAB1) gene associated with Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) in Vietnam and Philippines. ( 25797204 )
2015
11
Dengue haemorrhagic fever or dengue shock syndrome in children. ( 25860404 )
2015
12
A Prognostic Model for Development of Profound Shock among Children Presenting with Dengue Shock Syndrome. ( 25946113 )
2015
13
A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome. ( 24884822 )
2014
14
Early resuscitation of Dengue Shock Syndrome in children with hyperosmolar sodium-lactate: a randomized single blind clinical trial of efficacy and safety. ( 25189175 )
2014
15
Dengue shock syndrome in an infant. ( 25073530 )
2014
16
Dengue Shock Syndrome or Dehydration? The importance of considering clinical severity when classifying patients with dengue. ( 24403543 )
2014
17
Corticosteroids in the treatment of dengue shock syndrome. ( 24899817 )
2014
18
Association of IL1B -31C/T and IL1RA variable number of an 86-bp tandem repeat with dengue shock syndrome in Thailand. ( 24446526 )
2014
19
Differences in clinical features between children and adults with dengue hemorrhagic fever/dengue shock syndrome. ( 24437312 )
2013
20
Clinical characteristics of dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. ( 24046311 )
2013
21
Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. ( 23471635 )
2013
22
Serological characterization of dengue virus infections observed among dengue hemorrhagic fever/dengue shock syndrome cases in upper Myanmar. ( 23595687 )
2013
23
Role of cognitive parameters in dengue hemorrhagic fever and dengue shock syndrome. ( 24305068 )
2013
24
A patient with severe body aches without fever progressing to dengue shock syndrome. ( 24385064 )
2013
25
Possible cause of liver failure in patient with dengue shock syndrome. ( 23763890 )
2013
26
Factors associated with dengue shock syndrome: a systematic review and meta-analysis. ( 24086778 )
2013
27
Repeated dengue shock syndrome and 'dengue myocarditis' responding dramatically to a single dose of methyl prednisolone. ( 22521778 )
2012
28
Splenic rupture mimicking dengue shock syndrome. ( 23025068 )
2012
29
Association of mast cell-derived VEGF and proteases in Dengue shock syndrome. ( 22363824 )
2012
30
Peritoneal dialysis in dengue shock syndrome may be detrimental. ( 22529870 )
2012
31
A fatal combo of dengue shock syndrome with acute subdural hematoma. ( 22406795 )
2012
32
Sympathetic dysfunction as a cause for hypotension in dengue shock syndrome. ( 23075741 )
2012
33
A fatal case of bone marrow embolism of unknown cause masquerading clinically as dengue shock syndrome. ( 23455811 )
2012
34
Dengue shock syndrome with two atypical complications. ( 21842280 )
2012
35
Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. ( 22001756 )
2011
36
Infection-associated hemophagocytic syndrome among patients with dengue shock syndrome and invasive aspergillosis: a case series and review of the literature. ( 22299436 )
2011
37
Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. ( 21835036 )
2011
38
Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. ( 21922323 )
2011
39
Characterization of dengue shock syndrome in pediatric patients in El Salvador. ( 21490492 )
2011
40
Should colloid boluses be prioritized over crystalloid boluses for the management of dengue shock syndrome in the presence of ascites and pleural effusions? ( 21356095 )
2011
41
Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. ( 21212214 )
2011
42
National guidelines for diagnosis and management of dengue fever/dengue haemorrhagic fever and dengue shock syndrome. ( 21888156 )
2011
43
Dengue shock syndrome at the emergency room of Queen Sirikit National Institute of Child Health, Bangkok, Thailand. ( 22043755 )
2011
44
Effect of a single dose of methyl prednisolone as rescue medication for patients who develop hypotensive dengue shock syndrome during the febrile phase: a retrospective observational study. ( 21530348 )
2011
45
Risk factors of dengue shock syndrome in children. ( 21367851 )
2011
46
Laboratory predictors of dengue shock syndrome during the febrile stage. ( 20578515 )
2010
47
The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. ( 20943967 )
2010
48
Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. ( 20652028 )
2010
49
Persistent thrombocytopenia following dengue shock syndrome. ( 19381512 )
2009
50
Risk factors associated with development of dengue haemorrhagic fever or dengue shock syndrome in adults in Hospital Tengku Ampuan Afzan Kuantan. ( 20954558 )
2009

Variations for Dengue Shock Syndrome

Expression for Dengue Shock Syndrome

Search GEO for disease gene expression data for Dengue Shock Syndrome.

Pathways for Dengue Shock Syndrome

Pathways related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 CCL2 HLA-A IL1B IL1RN IL6 TNF
2
Show member pathways
12.88 CCL2 IL1B IL1RN IL6 TNF
3
Show member pathways
12.71 CCL2 HLA-A IL1B IL6 TNF
4
Show member pathways
12.5 CCL2 IL1B IL6 TNF
5 12.45 CCL2 IL1B IL1RN TNF
6
Show member pathways
12.26 CCL2 IL1B IL6 TNF
7 12.1 IL1B IL1RN IL6 TNF
8
Show member pathways
12.03 HLA-A IL1B IL6 TNF
9 12 CCL2 IL1B THBD TNF
10
Show member pathways
11.87 IL1B IL6 TNF
11 11.87 CCL2 IL1B IL6 TNF
12 11.84 CCL2 IL1B IL6 TNF
13
Show member pathways
11.83 CMA1 TNF TPSAB1
14 11.81 IL1B IL6 TNF
15 11.8 IL1B IL6 TNF
16 11.79 CCL2 IL1B IL6 TNF
17 11.69 IL1B IL6 TNF
18 11.69 CCL2 IL1B IL6 TNF
19
Show member pathways
11.6 IL1B IL6 TNF
20 11.55 IL1B IL6 THBD TNF
21 11.53 IL1B IL6 TNF
22 11.46 CCL2 IL1B TNF
23 11.43 IL1B IL6 TNF
24 11.35 CCL2 CMA1 IL1B IL6 TNF
25 11.3 IL1B IL6 TNF
26 11.3 IL1B IL6 TNF
27 11.27 CCL2 IL6 THBD
28 11.25 CCL2 IL1B IL6 TNF
29 11.23 IL1B IL6 TNF
30 11.2 IL1B IL6 TNF
31 11.16 IL1B IL6 TNF
32 11.1 CCL2 IL1B IL6 PLCE1 THBD TNF
33 11.04 CCL2 IL1B IL1RN IL6 TNF
34 11.02 IL1B TNF
35 11.02 IL6 TNF
36 10.95 IL6 TNF
37 10.95 CCL2 IL1B IL6 PLCE1 TNF
38 10.83 IL1B IL6
39 10.78 CCL2 IL1B TNF

GO Terms for Dengue Shock Syndrome

Cellular components related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 CCL2 IL1B IL1RN IL6 THBD TNF

Biological processes related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.83 CCL2 IL1B IL6
2 response to lipopolysaccharide GO:0032496 9.83 CCL2 IL1B IL6 THBD
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.82 IL1B IL6 TNF
4 cellular response to lipopolysaccharide GO:0071222 9.82 CCL2 IL6 TNF
5 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.8 IL1B IL6 TNF
6 activation of MAPK activity GO:0000187 9.79 IL1B PLCE1 TNF
7 inflammatory response GO:0006954 9.77 CCL2 IL1B IL1RN IL6 TNF
8 cellular response to organic cyclic compound GO:0071407 9.76 CCL2 IL1B TNF
9 humoral immune response GO:0006959 9.73 CCL2 IL6 TNF
10 response to heat GO:0009408 9.69 CCL2 IL6 MICB
11 positive regulation of interleukin-6 production GO:0032755 9.67 IL1B IL6 TNF
12 positive regulation of NF-kappaB import into nucleus GO:0042346 9.65 IL1B TNF
13 negative regulation of lipid catabolic process GO:0050995 9.64 IL1B TNF
14 positive regulation of chemokine production GO:0032722 9.63 IL6 TNF
15 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IL1B TNF
16 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.61 IL1B TNF
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL1B TNF
18 positive regulation of chemokine biosynthetic process GO:0045080 9.6 IL1B TNF
19 negative regulation of lipid storage GO:0010888 9.59 IL6 TNF
20 regulation of establishment of endothelial barrier GO:1903140 9.58 IL1B TNF
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 IL1B IL6 TNF
22 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.57 IL6 TNF
23 positive regulation of fever generation GO:0031622 9.54 IL1B TNF
24 sequestering of triglyceride GO:0030730 9.48 IL1B TNF
25 regulation of vascular endothelial growth factor production GO:0010574 9.46 CCL2 IL6
26 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.43 IL1RN IL6
27 protein kinase B signaling GO:0043491 9.43 CCL2 IL1B TNF
28 immune response GO:0006955 9.43 CCL2 HLA-A IL1B IL1RN IL6 TNF
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.33 CCL2 IL1B TNF
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IL1B TNF
31 fever generation GO:0001660 9.25 IL1B
32 response to glucocorticoid GO:0051384 8.92 CCL2 IL1RN IL6 TNF

Molecular functions related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL2 IL1B IL1RN IL6 TNF
2 interleukin-1 receptor binding GO:0005149 8.96 IL1B IL1RN

Sources for Dengue Shock Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....